VSee is proud to be selected as the digital health platform of choice for an upcoming NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation. Based out of UCLA this clinical trial is only the second such national trial examining post-stroke telerehabilitation.
The trial spans 29 hospitals and 202 patients, and seeks to overcome barriers like limited access to physical therapy clinics and poor patient motivation by adding 6 weeks of daily gamified, home-based telerehab sessions to a traditional stroke recovery regimen to improve arm functionality. The daily sessions will alternate between independent self-supervised sessions and therapist-supervised one-on-one sessions via VSee. The study will also look for resulting cost benefits such as reductions in transportation costs, caregiver resources, and hospital readmissions.
Phase 3 clinical trials demonstrate the efficacy and safety in a larger population, thus opening doors for Medicare and private payer reimbursement. This trial also points to opportunities in the $328M global stroke rehab market, where telehealth could disrupt traditional physical therapy with better adherence and lower costs, as well as gamified telerehabilitation in other areas, e.g. multiple sclerosis, spinal cord injury, and traumatic brain injury rehab.
Professor of neurology at UCLA and a co-principal investigator, Dr. Steven Cramer, MD affirms, “Reaching Phase 3 in a clinical trial of this scale is a hard-won milestone that has been twelve years in the making—one that wouldn’t have been possible without the right partners. VSee Health’s HIPAA-compliant platform has been instrumental in ensuring secure, seamless delivery of our interventions—critical for maintaining compliance and engagement in a large-scale trial like this.”
Dr. Milton Chen, PhD, Co-CEO of VSee Health adds, “We’re grateful and proud of VSee’s role in two of the only nationwide U.S. stroke tele-rehab trials. This Phase 3 trial validates telehealth as a scalable, cost-effective model for neurorehabilitation, and positions VSee as the go-to platform for the next wave of value-based virtual care that improves outcomes while reducing costs.”
This trial further solidifies VSee’s position as a key player in the telerehab market, building on VSee’s prior role in Phase 1 and Phase 2 of this neurology study.
Enrollment for the clinical trial begins Q3 2025 and will follow patients for eight months following completion of the rehabilitation treatment.
